Transgene provides update on PHOCUS study of Pexa-Vec in liver cancer

This article was originally published here

Sillajen has informed Transgene of the IDMC’s recommendation to stop enrolment in the study, as the study is unlikely to meet its primary objective by the time of

The post Transgene provides update on PHOCUS study of Pexa-Vec in liver cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply